Table 4.
Factors associated with progression-free survival in 94 patients who received conversion therapy for initially unresectable HCC.
| Univariate | Multivariate (Model 1)# | Multivariate (Model 2)# | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| HR | 95% CI | P | HR | 95% CI | P | HR | 95%CI | P | ||
| Age, y | > 60 vs ≦ 60 | 0.677 | 0.267 – 1.720 | 0.412 | ||||||
| Sex | Male vs Female | 1.934 | 0.465 – 8.037 | 0.364 | ||||||
| HBsAg-positive | Yes vs No | 1.725 | 0.534 – 5.568 | 0.362 | ||||||
| Tumor size, cm | > 10 vs ≦ 10 | 1.655 | 0.837 – 3.274 | 0.148 | ||||||
| Tumor number | multiple vs single | 1.440 | 0.796 – 2.607 | 0.228 | ||||||
| PVTT | Yes vs No | 1.719 | 0.939 – 3.146 | 0.079 | 1.430 | 0.745 – 2.746 | 0.282 | 1.688 | 0.851 – 3.348 | 0.134 |
| Macrovascular invasion |
Yes vs No | 1.645 | 0.884 – 3.062 | 0.116 | ||||||
| Extrahepatic metastasis | Yes vs No | 4.117 | 1.975 – 8.580 | < 0.001 | 3.583 | 1.659 – 7.738 | 0.001 | 2.439 | 1.111 – 5.356 | 0.026 |
| BCLC stage | Stage C vs A/B | 2.202 | 1.113 – 4.356 | 0.023 | NA | NA | ||||
| BCLC stage | Stage A vs B/C | 0.673 | 0.265 – 1.707 | 0.404 | ||||||
| AFP, ng/mL | > 400 vs ≦ 400 | 1.057 | 0.581 – 1.922 | 0.857 | ||||||
| SIRI | > 1.38 vs ≦ 1.38 | 1.751 | 0.968 – 3.170 | 0.064 | ||||||
| NLR | > 2.82 vs ≦ 2.82 | 1.515 | 0.839 – 2.735 | 0.168 | ||||||
| PLR | > 146vs ≦ 146 | 1.049 | 0.584 – 1.883 | 0.874 | ||||||
| Platelet count,×109/L | > 100 vs≦ 100 | 1.575 | 0.485 – 5.116 | 0.450 | ||||||
| ALT, U/L | > 40 vs ≦ 40 | 0.890 | 0.493 – 1.606 | 0.699 | ||||||
| AST, U/L | > 40 vs ≦ 40 | 1.244 | 0.553 – 2.796 | 0.597 | ||||||
| Ascites | Yes vs No | 2.779 | 1.318 – 5.860 | 0.007 | NA | NA | ||||
| Child-Pugh class | Class A vs B | 0.322 | 0.134 – 0.775 | 0.011 | 0.457 | 0.172 – 1.212 | 0.115 | 0.569 | 0.218 – 1.488 | 0.251 |
| ALBI grade | Grade1 vs 2/3 | 1.011 | 0.399 – 2.566 | 0.981 | ||||||
| ECOG PS | 0 vs 1 | 0.525 | 0.290 – 0.950 | 0.033 | 0.770 | 0.399 – 1.487 | 0.436 | 0.724 | 0.373 – 1.404 | 0.339 |
| Early AFP response * | Yes vs No | 0.378 | 0.181– 0.789 | 0.010 | – | – | – | 0.585 | 0.270 – 1.268 | 0.175 |
| Early tumor response† | Yes vs No | 0.433 | 0.237 – 0.789 | 0.006 | 0.576 | 0.302 – 1.097 | 0.093 | – | – | – |
| Successful conversion surgery | Yes vs No | 0.197 | 0.086 –0.454 | <0.001 | – | – | – | 0.248 | 0.099– 0.622 | 0.003 |
AFP, alpha fetoprotein; HCC, hepatocellular carcinoma; ECOG PS, Eastern Cooperative Oncology Group performance status; ALBI grade, albumin-bilirubin grade; ALT, alanine aminotransferase; NA, not adopted; AST, aspartate aminotransferase; BCLC stage, Barcelona-Clinic liver cancer stage; PLR, platelet to lymphocyte ratio; NLR, neutrophil to lymphocyte ratio; SIRI, systemic inflammation response index; CI, confidence interval; OR, odds ratio; PVTT, portal vein tumor thrombosis.
*Early AFP response: AFP reduced > 75% from baseline serum level at first follow-up.
†Early tumor response: Achievement of complete response (CR) and partial response (PR) using mRECIST at first follow-up.
Model 1 did not include early AFP response, successful conversion surgery, BCLC stage, and ascites into multivariate analysis to avoid collinearity.
Model 2 did not include early tumor response, BCLC stage, and ascites into multivariate analysis to avoid collinearity.
The bold values denote statistically significant results of the multivariate analysis.